Table 1.
Number and age of patients included in the analysis
| Site and Country | Reference |
Age (year) |
ASAQ | AL | AQ | AQ + SP | AS + SP | AS | CQ + SP | DP | Total | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | Mininum | Maximum | |||||||||||
| Burkina Faso |
[9] |
2.0 |
0.5 |
5 |
750 |
|
|
|
|
|
|
|
750 |
| Cameroon |
[7] |
6.2 |
1.0 |
65 |
110 |
56 |
|
|
|
|
|
|
166 |
| Gabon |
[8]* |
5.5 |
1.3 |
11 |
108 |
|
110 |
|
|
|
|
|
218 |
| Madagascar |
[9] |
7.4 |
1.4 |
53 |
119 |
60 |
|
|
|
|
|
|
179 |
| Mali, Boulouga |
[7] |
4.7 |
0.9 |
24 |
135 |
68 |
|
|
|
|
|
|
203 |
| Mali, Bancoumana |
[10] |
3.0 |
0.6 |
56 |
252 |
|
|
|
249 |
252 |
|
|
753 |
| Rwanda, Kicukiro |
[11]* |
3.3 |
1.0 |
5 |
74 |
|
|
74 |
|
|
|
75 |
223 |
| Rwanda, Mashesha |
[11]* |
3.0 |
1.1 |
5 |
89 |
|
|
93 |
|
|
|
87 |
269 |
| Rwanda, Rukara |
[11]* |
2.1 |
1.0 |
5 |
89 |
|
|
91 |
|
|
|
90 |
270 |
| Senegal, Keur-Socé |
[7] |
9.0 |
1.0 |
15 |
264 |
128 |
|
|
|
|
|
|
392 |
| Senegal, Mlomp |
[11]* |
5.0 |
0.9 |
64 |
160 |
|
160 |
|
|
|
|
|
320 |
| Uganda, Apac |
[13]* |
1.8 |
0.5 |
47 |
174 |
|
|
183 |
|
|
185 |
|
542 |
| Uganda, Jinja |
[13]* |
3.6 |
0.5 |
65 |
189 |
|
|
186 |
|
|
168 |
|
543 |
| Uganda, Tororo |
[13,14]* |
1.6 |
0.5 |
56 |
398 |
204 |
|
181 |
|
|
166 |
|
949 |
| Zanzibar, Kivungue |
[12] |
2.5 |
0.5 |
7 |
148 |
149 |
|
|
|
|
|
|
297 |
| Zanzibar, Micheweni |
[12] |
2.1 |
0.5 |
5 |
54 |
51 |
|
|
|
|
|
|
105 |
| Total | 3.0 | 0.5 | 65 | 3113 | 716 | 270 | 808 | 249 | 252 | 519 | 252 | 6179 | |
Legend: * studies including grading of intensity AQ, amodiaquine; AL, artemether-lumefantrine; AS, artesunate; DP, dihydroartemisinin-piperaquine; CQ, chloroquine; SP, sulphadoxine-pyrimethamine.